The US Food and Drug Administration (FDA) has authorised a booster dose of the Pfizer Inc (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine for those aged 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the virus, Reuters news agency reported on Thursday.
FDA Acting Commissioner Janet Woodcock stated that this change to the vaccine's emergency use authorisation will allow boosters for groups such as health care workers, teachers and day care staff, grocery workers and those in homeless shelters or prisons.
An outside FDA panel of advisers voted against Pfizer's proposition that boosters were needed by everyone but said that evidence showed they were helpful to older people and those at high risk.
European Commission approves GSK's Arexvy for adults aged 18 and over
PhotonPharma adds Dr. William Warren to board
GSK wins European Commission approval for Shingrix prefilled syringe
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Avetra unveils site-centric CRO operating model
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s